- Home
- / VistaGen Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
VistaGen Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3
2024-10-29
Market Capitalization
$82.5 M
2024-10-29
Revenue
$1.3 M
FY, 2026
CreditSafe Score
?
Score changed on Jul 19, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 | FY, 2026 |
|---|---|---|---|---|---|
| Revenue | 1.1M | (227.0K) | 1.1M | 486.0K | 1.3M |
| General and administrative expense | 13.5M | 14.7M | 14.1M | 17.1M | 18.4M |
| Operating expense total | 48.9M | 59.0M | 34.1M | 56.5M | 73.4M |
| EBIT | (47.8M) | (59.3M) | (33.0M) | (56.0M) | (72.1M) |
| EBIT margin, % | -4308.7% | 26109.3% | -3103.5% | -11517.1% | -5683.7% |
| Interest income | 19.9K | 26.0K | 3.4M | ||
| Interest expense | 4.6M | 2.4M | |||
| Pre tax profit | (47.8M) | (59.2M) | (29.4M) | (51.4M) | (69.7M) |
| Income tax expense | 3.0K | 5.9K | 4.0K | 7.0K | 7.0K |
| Net Income | (47.8M) | (59.2M) | (29.4M) | (51.4M) | (69.7M) |
| EPS | (0.2) | (8.5) | (1.5) | (1.7) | (1.8) |